GIP and GLP-1 receptor co-agonist
Tirzepatide 5 mg subcutaneous once weekly
TIRZ_SC_5MG_QW
Related
- All doses pooled: Tirzepatide injection
- Tirzepatide 1 mg subcutaneous once weekly
- Tirzepatide 10 mg subcutaneous once weekly
- Tirzepatide 15 mg subcutaneous once weekly
- Tirzepatide maximum tolerated dose injection once weekly
- Tirzepatide subcutaneous once weekly, maximum tolerated dose: 10 or 15 mg
- Tirzepatide 12 mg injection once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.58 (-1.91 to -1.25) | 0.89 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.15 (-0.68 to 0.41) | 0.57 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.89 (-2.37 to -1.29) | 0.79 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.30 (-1.70 to -0.81) | 0.62 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.84 (-2.66 to -0.57) | 0.77 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -3.83 (-5.92 to -1.80) | 0.81 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -6.14 (-8.83 to -2.42) | 0.84 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -3.41 (-7.58 to 1.58) | 0.61 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -7.46 (-9.69 to -4.71) | 0.68 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -6.04 (-10.46 to -0.18) | 0.69 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 13.28 (3.12 to 41.29) | 0.76 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Tirzepatide 10 mg subcutaneous once weekly | OR 0.50 (0.22 to 1.05) | 0.35 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 17.29 (1.30 to 64.83) | 0.67 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.05 (0.00 to 0.90) | 0.80 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.90 (1.16 to 7.34) | 0.42 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.90 (0.03 to 25.38) | 0.58 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.54 (0.17 to 1.54) | 0.66 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -3.87 (-8.50 to 0.89) | 0.69 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -1.49 (-6.62 to 3.36) | 0.81 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -4.36 (-15.77 to 8.49) | 0.73 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 18.54 (4.51 to 81.36) | 0.82 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 5.65 (1.15 to 28.23) | 0.61 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.73 (0.56 to 0.96) | 0.67 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.18 (0.76 to 1.87) | 0.61 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.07 (1.49 to 2.86) | 0.60 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.79 (1.16 to 2.76) | 0.63 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.23 (1.68 to 2.95) | 0.34 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.29 (1.41 to 3.79) | 0.37 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 1.43 (0.16 to 9.76) | 0.55 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 5.92 (0.71 to 52.71) | 0.12 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.70 (0.01 to 47.78) | 0.57 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -13.04 (-18.53 to -3.14) | 0.43 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 1.79 (-6.09 to 9.60) | 0.45 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.08 (0.53 to 2.12) | 0.53 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.11 (2.13 to 4.50) | 0.59 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.62 (2.44 to 8.76) | 0.47 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.99 (1.75 to 5.13) | 0.30 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.42 (1.76 to 6.72) | 0.28 |
| Type 1 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Placebo | MD -0.29 (-1.14 to 0.51) | 0.66 |
| Type 1 diabetes | Total daily insulin dose change | weeks 12 to 40 (target week 26) | Placebo | MD -0.18 (-0.41 to 0.06) | 0.66 |
| Type 1 diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.52 (0.01 to 41.53) | 0.61 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Serious adverse events | longest follow-up | Placebo | HR 1.90 (0.39 to 9.90) | 0.31 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.07 (0.13 to 8.18) | 0.60 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Nausea | longest follow-up | Placebo | HR 2.95 (0.87 to 9.60) | 0.52 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Vomiting | longest follow-up | Placebo | HR 1.95 (0.24 to 14.78) | 0.74 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Diarrhea | longest follow-up | Placebo | HR 1.44 (0.46 to 4.24) | 0.58 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Constipation | longest follow-up | Placebo | HR 3.41 (0.78 to 14.63) | 0.24 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 1.94 (0.22 to 20.20) | 0.50 |
Trials
- S00342679 randomized · 24 weeks
- S0030072024 · 24 randomized · 12 weeks
- SURPASS-6A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)2020 · 1,428 randomized · 52 weeks
- NCT04093752A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea2019 · 917 randomized · 40 weeks
- SURMOUNT-1Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)2019 · 2,539 randomized · 72 weeks
- NCT03861039A Phase 3, Long-Term Safety Study of Tirzepatide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus (SURPASS J-combo)2019 · 443 randomized · 52 weeks
- SURPASS-3A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes2019 · 1,444 randomized · 52 weeks
- SURPASS-5Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin2019 · 475 randomized · 40 weeks
- SYNERGY-NASHA Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)2019 · 190 randomized · 52 weeks
- SURPASS-1A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone2019 · 478 randomized · 40 weeks
- SURPASS-4Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)2018 · 2,002 randomized · 104 weeks
- NCT03322631A Multiple-Ascending Dose Study in Japanese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY32981762017 · 48 randomized · 8 weeks
- NCT03131687A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus2017 · 318 randomized · 26 weeks